The Dec. 27, 2024, Food and Drug Administration (FDA) approval of the subcutaneous injection formulation of Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) for patients with solid tumors opened up ...

Opdivo Qvantig (nivolumab and hyaluronidase ... second drug in the PD-1/PD-L1 inhibitor class to be cleared in a subcutaneous injection form by the FDA after Roche's Tecentriq Hybreza ...

FDA Accepts Nivolumab Subcutaneous Injection Application, With Potential to Boost Access to PD-1 Inhibitors ...

FDA Accepts Nivolumab Subcutaneous Injection Application, With Potential to Boost Access to PD-1 Inhibitors ...

All lines have been placed on mute to prevent any background noise. There will be a question-and-answer session at the ...

Bristol Myers Squibb BMY announced that it has obtained a positive opinion from the Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicines Agency for two of its drugs. The ...

Opdivo contains the medicine nivolumab. It acts on proteins ... Opdivo Qvantig is a subcutaneous (under-the-skin) injection in your stomach area or thigh. It is given by a healthcare provider ...

Sanofi has partnered with drug delivery specialist Enable Injections to develop the subcutaneous formulation. At JP Morgan last month, pharmaphorum caught up with Paul Hastings, the CEO of Nkarta ...